# A Study of Combination Therapy in NSCLC

> **NCT04544644** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AK104+anlotinib

## Key facts

- **NCT ID:** NCT04544644
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2022-09
- **Final completion:** 2023-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544644, "A Study of Combination Therapy in NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04544644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*